Therapeutic efficacy of extracorporeal shock wave combined with hyaluronic acid on knee osteoarthritis

Shi-Chen Liu, MMa, Xiao-Feng Qiao, MMa, Qing-Xi Tang, MMb, Xiao-Guang Li, MMc, Jian-Hua Yang, MDd, Tian-Qi Wang, MBA, Ya-Jie Xiao, MBA, Jian-Min Qiao, MBA,∗

Abstract
This retrospective study investigated the efficacy and safety of extracorporeal shock wave (EPSW) combined with hyaluronic acid (HA) for patients with knee osteoarthritis (KOA).

This retrospective study included 70 patients with KOA. Of those subjects, 35 of them received EPSW combined HA, and were allocated to a treatment group, while the other 35 participants received HA alone and were allocated to a control group. Patients in both groups were treated for a total of 8 weeks. The primary outcome was measured by visual analog scale (VAS). The secondary outcomes were measured by Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), and knee injury and osteoarthritis outcome score (KOOS). In addition, adverse events (AEs) were also evaluated. All outcomes were measured before and after the treatment.

After the treatment, patients in the treatment group exhibited better efficacy in VAS (\(P<.01\)), WOMAC scale (pain, \(P<.01\); function, \(P<.01\); and stiffness, \(P<.01\)), and KOOS scores (pain, \(P<.01\); function in daily living, \(P<.01\); symptoms, \(P<.01\); sport and recreation, \(P<.01\); and quality of life, \(P<.01\)), than patients in the control group. In addition, no significant differences regarding the AEs were found between 2 groups.

The findings of this study demonstrated that the efficacy of EPSW combined with HA is superior to the HA alone for patients with KOA.

Abbreviations: AEs = adverse events, EPSW = extracorporeal shock wave, HA = hyaluronic acid, KOA = knee osteoarthritis, KOOS = knee injury and osteoarthritis outcome score, VAS = visual analog scale, WOMAC = Western Ontario and McMaster Universities Osteoarthritis Index.

Keywords: efficacy, extracorporeal shock-wave therapy, hyaluronic acid, knee osteoarthritis

1. Introduction
Knee osteoarthritis (KOA) is one of most common inflammatory disorders for knee joint among the elderly population.[1,2] It often manifests with severe pain, stiffness, limitation of joint movement, and disability.[3,4] Previous epidemiological studies have reported that the prevalence of KOA is about 16% to 75% in Asian females.[5–7] The other studies also reported that more than 29.25% of female and 24.71% of males over 70 years old suffer from this disorder.[8–10]

A variety of management are used to treat this condition effectively,[11–17] especially for extracorporeal shock wave (EPSW) and hyaluronic acid (HA). A lot of previous clinical studies have assessed the efficacy of ESW or HA for the treatment of KOA.[18–23] However, both of them has limited efficacy for some patients. Moreover, no clinical studies have reported to utilize the combination of EPSW and HA for the treatment of KOA. Thus, in order to achieve more promising outcome efficacy, this retrospective study aimed to explore the efficacy of EPSW combined with HA for the treatment of patients with KOA.

2. Methods/design

2.1. Hypothesis
The hypothesis of this study was that the efficacy of EPSW plus HA would be superior to the HA monotherapy in patients with KOA.

2.2. Ethical consideration
The present retrospective study has been approved by the Ethical Committee of First Affiliated Hospital of Jiamusi University. The
written informed consent from individual patient has been waived because all the data of this study were collected from the completed medical records.

2.3. Design
All cases were collected between December 2016 and November 2018 at the First Affiliated Hospital of Jiamusi University. A total of 70 patients with KOA were included and were divided into a treatment group (n=35, received EPSW and HA) and a control group (n=35, received HA alone) according to the different treatments they received. All patients in both groups were treated for a total of 8 weeks. All outcomes were measured before and after the treatment. All patients, researchers, and outcomes were not blinded in this retrospective study. However, the data analyst was masked to the group allocation and treatment.

2.4. Patients
Patients were included if they aged from 50 to 85 years old and were clinically diagnosed as KOA. In addition, all of them had average pain intensity of knee visual analog scale (VAS) ≥4 over the past 6 months. Patients were excluded if they were pregnant, breastfeeding, history of knee surgery, local knee tumors, and trauma. In addition, they were also excluded if they received other therapies, such as acupuncture, moxibustion, or medications for KOA during the study period, except the EPSW and HA.

2.5. Intervention schedule
All patients in both groups received an injection of HA in the affected knee joint (2.5 ml of 1% HA solution), once for a period of 4-week within a total of 8-week treatment period. Additionally, the patients in the treatment group also received EPSW (0.25 mJ/mm² for 4000 pulses in total and a frequency of 15 Hz/s) by using EPSW Device (Sonothera, Hanil Tm Co Ltd, Korea), once weekly for a total of 8 weeks.

2.6. Outcome measurements
Primary outcome was measured by using 0 to 10cm VAS scale, with 0 of no pain, and 10 of severest pain. The secondary outcomes were assessed by the Western Ontario and McMaster Universities Arthritis Index (WOMAC), and self-reported knee injury and osteoarthritis outcome score (KOOS). WOMAC tool consists of 3 subscales of pain, function, and stiffness. KOOS tool includes 5 subscales with a total of 42 items. Each subscale is transformed to a 0 to 100 scale. In addition, adverse events (AEs) were also assessed. All outcomes were evaluated before and after the treatment.

2.7. Statistical analysis
All outcome data were analyzed by a professional statistician using SAS package (Version 9.1; SAS Institute Inc, Cary, North Carolina). All continuous data were analyzed by using t test or Mann–Whitney rank sum test. All categorical data were analyzed by using Fisher exact test. The value of P < .05 was considered as the statistically significant (2-side).

Sample size was calculated based on the change of VAS score with α=0.5, β=0.8, and with an assumed 15% drop-out rate.

Therefore, the required sample size of for this study was 70 patients in total and 35 subjects in each group.

3. Results
The characteristic values of all patients in both groups before the treatment are showed in Table 1. The comparison of all these values did not differ significantly between the 2 groups (Table 1).

### Table 1
Comparison of characteristics before the treatment.

| Characteristics                  | Treatment group (n = 35) | Control group (n = 35) | P  |
|----------------------------------|--------------------------|------------------------|----|
| Mean age, yr                     | 66.8 (9.1)               | 68.2 (10.3)            | .55|
| Sex                              |                          |                        |    |
| Male                             | 13 (37.1)                | 15 (42.9)              | .63|
| Female                           | 22 (62.9)                | 20 (57.1)              | .63|
| Race (Chinese Han)               | 35 (100.0)               | 35 (100.0)             | –  |
| BMI, kg/m²                       | 25.9 (3.1)               | 26.4 (3.4)             | .52|
| Duration of disease, yr          | 14.0 (3.8)               | 15.2 (4.2)             | .21|
| VAS scale                        | 6.5 (1.6)                | 6.8 (1.9)              | .47|
| WOMAC score                     |                          |                        |    |
| Total                            | 52.0 (11.1)              | 53.9 (11.8)            | .49|
| Pain                             | 12.6 (3.2)               | 13.0 (3.4)             | .61|
| Stiffness                        | 4.5 (1.6)                | 4.7 (1.8)              | .62|
| Function                         | 34.8 (7.9)               | 36.1 (8.3)             | .50|
| KOOS score                       |                          |                        |    |
| Pain                             | 66.1 (9.6)               | 67.9 (10.4)            | .45|
| Function in daily living         | 70.3 (12.0)              | 72.7 (13.5)            | .43|
| Symptoms                         | 64.4 (10.7)              | 66.2 (12.2)            | .51|
| Sport and recreation             | 34.8 (9.3)               | 36.1 (10.0)            | .57|
| Quality of life                  | 44.7 (15.3)              | 46.6 (16.1)            | .61|
| Previous treatment               |                          |                        |    |
| Medications                      | 34 (97.1)                | 35 (100.0)             | .49|
| Physical therapy                 | 20 (57.1)                | 18 (51.4)              | .63|
| Acupuncture                      | 21 (60.0)                | 15 (42.9)              | .15|

Data are present as mean± standard deviation or number (%). BMI = body mass index, KOOS = knee injury and osteoarthritis outcome score, VAS = visual analog scale. WOMAC = Western Ontario and McMaster Universities Osteoarthritis Index.

### Table 2
Comparison of VAS after treatment (change from pretreatment).

| Outcome                  | Treatment group (n = 35) | Control group (n = 35) | Difference | P  |
|--------------------------|--------------------------|------------------------|------------|----|
| VAS                      | −1.9 (−3.3, −1.0)        | −4.1 (−5.9, −2.8)      | −2.2 (−2.9, −1.4) | < .01 |

Data are present as mean± standard deviation. VAS = visual analog scale.

3.3. Discussion
Numerous clinical studies have reported the efficacy of HA for the treatment of KOA, and have achieved exciting efficacy.
However, it still has limited efficacy for some patients, and also accompanied a couple of AEs. Thus, it would be great if an alternative therapy with fewer AEs can be used as adjunctive therapy to HA for the treatment of KOA. Fortunately, EPSW is a new alternative therapy that also can be used to treat a variety of pain conditions with great effect and fewer AEs. Additionally, no study has reported the efficacy of EPSW combined with HA for the treatment of KOA.

Presently, to our best knowledge, this study first investigated the efficacy and safety of the combination of EPSW and HA for the treatment of patients with KOA. In this study, we compared the efficacy and safety of EPSW plus HA with HA alone. The results of this study showed that patients who received EPSW plus HA showed better efficacy in VAS, WOMAC, and KOOS, than patients who received HA only. In addition, both groups had a similar safety profile. It indicated that the efficacy of EPSW plus HA for the treatment of KOA is much better than HA alone.

This retrospective study has 4 limitations. First, all patients and researchers were not blinded to the treatment and group allocation, because this study just analyzed the data from the completed medical records. Thus, it may increase the selection risk of bias. Second, all the outcome assessors were also not masked to the group allocation, which may increase the detection risk of bias in this study. Third, no randomization was applied in this study, which may affect patient selection in this study, thus, may increase the selection risk of bias. Fourth, this study did not include follow-up period visits after the treatment. Therefore, long term efficacy of EPSW plus HA for the treatment of KOA is still needed to be explored in future studies.

5. Conclusion

The results of this study demonstrated that the efficacy of EPSW and HA is superior to the HA alone for the treatment of patients with KOA.

Author contributions

Conceptualization: Shi-Chen Liu, Xiao-Feng Qiao, Qing-Xi Tang, Xiao-Guang Li, Jian-Hua Yang, Jian-Min Qiao.
Data curation: Shi-Chen Liu, Xiao-Feng Qiao, Qing-Xi Tang, Xiao-Guang Li, Jian-Hua Yang, Tian-Qi Wang, Ya-Jie Xiao, Jian-Min Qiao.
Methodology: Shi-Chen Liu, Jian-Hua Yang, Ya-Jie Xiao.
Project administration: Tian-Qi Wang, Jian-Min Qiao.
Resources: Shi-Chen Liu, Qing-Xi Tang, Xiao-Guang Li, Tian-Qi Wang, Ya-Jie Xiao.
Software: Shi-Chen Liu, Jian-Hua Yang.
Supervision: Qing-Xi Tang, Jian-Min Qiao.
Validation: Xiao-Feng Qiao, Qing-Xi Tang, Jian-Hua Yang, Tian-Qi Wang, Jian-Min Qiao.
Visualization: Xiao-Feng Qiao, Qing-Xi Tang, Xiao-Guang Li, Jian-Hua Yang, Tian-Qi Wang, Jian-Min Qiao.
Writing – original draft: Shi-Chen Liu, Xiao-Feng Qiao, Tian-Qi Wang, Ya-Jie Xiao, Jian-Min Qiao.
Writing – review and editing: Shi-Chen Liu, Qing-Xi Tang, Xiao-Guang Li, Jian-Hua Yang, Tian-Qi Wang, Ya-Jie Xiao, Jian-Min Qiao.

References

[1] Mora JC, Przkora R, Cruz-Almeida Y. Knee osteoarthritis: pathophysiology and current treatment modalities. J Pain Res 2018;11:2189–96.
[2] Rodriguez-Merchan FC. Topical therapies for knee osteoarthritis. Postgrad Med 2018;130:607–12.
[3] Madaleno FO, Santos BA, Araújo VL, et al. Prevalence of knee osteoarthritis in former athletes: a systematic review with meta-analysis. Braz J Phys Ther 2018;22:437–51.

[4] Dall’Oca C, Cengarle M, Costanzo A, et al. Current concepts in treatment of early knee osteoarthritis and osteochondral lesions; the role of biological augmentations. Acta Biomed 2017;88:5–10.

[5] Allen KD. Racial and ethnic disparities in osteoarthritis phenotypes. Curr Opin Rheumatol 2010;22:528–32.

[6] Zhang Y, Xu L, Nevitt MC, et al. Comparison of the prevalence of knee osteoarthritis between the elderly Chinese population in Beijing and whites in the United States: the Beijing osteoarthritis study. Arthritis Rheum 2001;44:2065–71.

[7] Felson DT, Nevitt MC, Zhang Y, et al. High prevalence of lateral knee osteoarthritis in Beijing Chinese compared with Framingham Caucasian subjects. Arthritis Rheum 2002;46:1217–22.

[8] Liu Y, Zhang H, Liang N, et al. Prevalence and associated factors of knee osteoarthritis in a rural Chinese adult population: an epidemiological survey. BMC Public Health 2015;16:94.

[9] Tang X, Wang S, Zhan S, et al. The prevalence of symptomatic knee osteoarthritis in China: results from the China health and retirement longitudinal study. Arthritis Rheumatol 2016;68:648–53.

[10] Heidari B. Knee osteoarthritis prevalence, risk factors, pathogenesis and features: part I. Caspian J Intern Med 2011;2:203–12.

[11] Frauoli A, Mennuni G, Fontana M, et al. Efficacy of spa therapy, balneotherapy, and mud-bath therapy in the management of knee osteoarthrits. A Systematic Review. Biomed Res Int 2018;2018:1042576.

[12] Tian K, Cheng H, Zhang J, et al. Intrarticular injection of methylprednisolone for reducing pain in knee osteoarthritis: a systematic review and meta-analysis. Medicine (Baltimore) 2018;97:e0240.

[13] Yang M, Jiang L, Wang Q, et al. Traditional Chinese medicine for knee osteoarthritis: an overview of systematic review. PLoS One 2017;12:e0189884.

[14] Biscchia S, Tuddisco C. Hyaluronic acid vs corticosteroids in symptomatic knee osteoarthritis: a mini-review of the literature. Clin Cases Miner Bone Metab 2017;14:182–8.

[15] Tang XB, Wang J, Dong PL, et al. A meta-analysis of patellar replacement in total knee arthroplasty for patients with knee osteoarthritis. J Arthroplasty 2018;33:960–7.

[16] Li JQ, Guo W, Sun ZG, et al. Cupping therapy for treating knee osteoarthritis: the evidence from systematic review and meta-analysis. Complement Ther Clin Pract 2017;28:152–60.

[17] Steinhaus ME, Christ AB, Cross MB. Total knee arthroplasty for knee osteoarthritis: support for a foregone conclusion? HSS J 2017;13:207–10.

[18] Kang S, Gao F, Han J, et al. Extracorporeal shock wave treatment can normalize painful bone marrow edema in knee osteoarthritis: a comparative historical cohort study. Medicine (Baltimore) 2018;97:e9796.

[19] Imamura M, Alamino S, Hsing WT, et al. Radial extracorporeal shock wave therapy for disabling pain due to severe primary knee osteoarthritis. J Rehabil Med 2017;49:54–62.

[20] Kim JH, Kim JY, Choi CM, et al. The dose-related effects of extracorporeal shock wave therapy for knee osteoarthritis. Ann Rehabil Med 2015;39:616–23.

[21] Su K, Bai Y, Wang J, et al. Comparison of hyaluronic acid and PRP intraarticular injection with combined intra-articular and intrasosseous PRP injections to treat patients with knee osteoarthritis. Clin Rheumatol 2018;37:1341–50.

[22] Ricci M, Micheloni GM, Berti M, et al. Clinical comparison of oral administration and viscosupplementation of hyaluronic acid (HA) in early knee osteoarthrits. Musculoskelet Surg 2017;101:45–9.

[23] Zhang H, Zhang K, Zhang X, et al. Comparison of two hyaluronic acid formulations for safety and efficacy (CHASE) study in knee osteoarthrits: a multicenter, randomized, double-blind, 26-week non-inferiority trial comparing Durolane to Artz. Arthritis Res Ther 2015;17:51.

[24] Chen WH, Liu XX, Tong PJ, et al. Diagnosis and management of knee osteoarthritis: Chinese medicine expert consensus (2015). Chin J Integr Med 2016;22:150–3.

[25] Kelly AM. The minimum clinically significant difference in visual analogue scale pain score does not differ with severity of pain. Emerg Med J 2001;18:205–7.

[26] Bellamy N, Buchanan WW, Goldsmith CH, et al. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to anti-rheumatic drug therapy in patients with osteoarthrits of the hip or knee. J Rheumatol 1988;15:1833–40.

[27] Roos EM, Lohmander LS. The knee injury and osteoarthritis outcome score (KOOS): from joint injury to osteoarthritis. Health Qual Life Outcomes 2003;1:64.